Pulse Biosciences Priced, Nasdaq: PLSE

Developing a device that uses pulsed electric fields to treat solid tumors.

Industry: Health Care

Latest Trade: $15.02 0.00 (0.0%)

First Day Return: +4.3%

Return from IPO: +275.5%

Industry: Health Care

We are a development-stage medical device company using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling or NPES. NPES is a local and drug-free technology that utilizes ultra-short, nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. We believe that NPES can induce a variety of cellular responses including secretion, apoptosis and necrosis by modulating the NPES pulses, making it applicable to a wide variety of cell types and therapeutic applications. One of the more promising applications of NPES is the treatment of solid tumors, where pre-clinical data developed by Pulse Biosciences and others have shown that NPES provides effective local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the treated cells. We believe we will establish NPES as a new treatment modality across a variety of applications, including both veterinary and human oncology, dermatology, aesthetics and other minimally invasive applications where current ablation modalities do not provide the benefits of NPES.
more less
IPO News for Pulse Biosciences
more
IPO Data
IPO File Date 12/22/2015
Offer Price $4.00
Price Range $4.00 - $4.00
Offer Shares (mm) 5.0
Deal Size ($mm) $20
IPO Data
IPO Date 05/17/2016
Offer Price $4.00
Price Range $4.00 - $4.00
Offer Shares (mm) 5.0
Deal Size ($mm) $20
Underwriters
more
Company Data
Headquarters Burlingame, CA
Founded 2014
Employees 12
Website www.pulsebiosciences.com